MTOR and glioma: While single agent MEK or mTOR inhibition remains a promising strategy for NF1-associated gliomas belonging to the molecular low-grade group with biallelic NF1 inactivation only, those NF1-associated gliomas with additional oncogenic alterations belonging to the molecular high-grade group likely require combinatorial treatment approaches to be evaluated in future clinical trials.